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ABSTRACT 
Objective 
To evaluate Mepolizumab for adolescents with severe eosinophilic asthma who failed on or were 
ineligible for Omalizumab. 
 
Methods 
Retrospective observational study assessing the effect of Mepolizumab on asthma attacks, blood 
eosinophil count, pulmonary function (fractional exhaled nitric oxide concentration (FeNO), forced 
expiratory volume in 1s (FEV1)), Asthma Control Test (ACT) and Paediatric Asthma Quality of Life 
Questionnaire (PAQLQ) scores. Data evaluated during the first 4 and after 12 months. 
 
Results 
Seven adolescents (mean age 13.9±1.9, range 11-17 years; sex 5M:2F) received 12 Mepolizumab 
doses (100mg monthly subcutaneous injection) with no serious adverse reactions. Twelve months 
pre-Mepolizumab, mean number of severe asthma attacks per child requiring high dose oral steroids 
was 5.0±1.73 (4 hospitalised, mean hospitalisations 1.8±0.96). Reduced frequency of severe attacks, 
mean 1.1±1.07, 3.1±3.13 after 4 and 12 doses. One patient hospitalised twice, 1 avoided severe 
attacks. Blood eosinophils decreased in all (mean pre-treatment 0.8±0.64 x 109, 0.1±0.06 x 109 cells/L 
after 3 or 4 doses). After 3 doses, PAQLQ scores improved/remained static in 5/7 patients (71%), 
mean ∆PAQLQ 0.9±1.84. After 4 doses, ACT improved in 5/7 patients (71%), mean ∆ACT 3.0±4.55, 
FEV1 z-score improved in 2/7 patients (29%), mean ∆FEV1 z-score -0.2±0.68. After 12 doses, ACT 
improved in 3/7 patients (43%) from baseline, mean ∆ACT 1.7±7.25. FEV1 z-score improved in 2/7 
patients, mean ∆FEV1 z-score -2.2±2.14. Mean ∆FeNO -15±29, -37±126 ppb after 4 and 12 doses. 
 
Conclusion 
Mepolizumab is well tolerated, reduces exacerbation risk, may improve asthma control and quality 
of life but does not improve lung function.    
 
  
INTRODUCTION 
Omalizumab is a recombinant monoclonal antibody (IgG1) targeting IgE for use in severe allergic 
asthma. However, it is not a suitable treatment in some patients because of their IgE level and/or 
weight [1], and a small number of eligible patients do not respond to it [2]. Mepolizumab, an anti-
interleukin-5 (IL-5) monoclonal antibody is an emerging therapy approved for use in adults with 
severe refractory eosinophilic asthma [3,4] and has been shown to reduce asthma attacks in adults 
and adolescents [5,6,7].  Mepolizumab has been accepted by NICE and the Scottish Medicines 
Commission for restricted use as an add-on treatment for severe refractory eosinophilic asthma in 
adult patients, and more recently for use in children from 6 years in the EU [3,8]. Although 28 
adolescents who were 12 years and upwards were eligible for inclusion in the pivotal studies, only 19 
adolescents aged 12-17 years old were treated with Mepolizumab [9,10,11].  
 
In our experience, children with severe eosinophilic asthma who are poorly responsive to standard 
therapies, are not eligible for Omalizumab or fail to respond to it, are clinically difficult to manage. 
Our paediatric centre obtained local approval for use of Mepolizumab as an unlicensed medicine in 
such adolescents with severe eosinophilic asthma. Here we review our experience of Mepolizumab 
on acute asthma attacks, asthma control (Asthma Control Test, (ACT)) [12], pulmonary function 
(fractional exhaled nitric oxide concentration (FeNO) and forced expiratory volume in 1s (FEV1)), 
blood eosinophil count, and quality of life (Paediatric Asthma Quality of Life Questionnaire (PAQLQ)). 
We performed an initial evaluation after 4 months as is recommended for Omalizumab [13] and 
after 12 months treatment. 
 
METHODS 
Study participants 
We retrospectively analysed data from adolescents offered Mepolizumab at the Royal Hospital for 
Children, Glasgow between October 2016 – January 2018. Adolescents were offered Mepolizumab if 
they had severe eosinophilic asthma and were not eligible for Omalizumab (n=7). 
 
Eosinophilic asthma was defined as a blood eosinophil count >300 cells/μL or fractional exhaled 
nitric oxide concentration (FeNO) ≥50 ppb in the previous year [9]. All adolescents received high-
dose inhaled corticosteroids (ICS), long-acting beta-adrenoceptor agonist (LABA) and had a history of 
≥3 severe asthma attacks needing systemic corticosteroids in the previous year. Six adolescents 
received leukotriene receptor antagonists, 3 received slow-release oral theophylline and 4 received 
daily oral steroids. All had low ACT scores (mean 10.4) prior to Mepolizumab.  
 
Each patient received 12 Mepolizumab doses of 100 mg administered subcutaneously at monthly 
intervals, with evaluation after 4 and 12 doses. Long-term medications were not adjusted during 
Mepolizumab treatment. 
 
Pulmonary function testing 
Pulmonary function was measured using a Jaeger Masterscreen Body Plethysmograph (Jaeger V5.4, 
Germany) and FeNO measured with an electrochemical analyser (Aerocrine NIOX MINO, Sweden) by 
an experienced paediatric physiologist in accordance with American Thoracic Society 
(ATS)/European Respiratory Society (ERS) standards [14,15,16]. 
 
Consent 
As Mepolizumab is an unlicensed drug in adolescents, informed verbal consent was obtained. As this 
study was a retrospective review of results from our clinical practice, we did not seek informed 
consent for review of anonymised patient data.  
 
Statistical analysis 
Data expressed as means and SDs. Forced expiratory volume in 1 s (FEV1) expressed as z-scores using 
GLI reference ranges [17]. 
 
RESULTS 
Seven adolescents (mean age 13.9±1.9, range 11-17 years; 5 males, 2 females; mean weight 
62.0±10.04 kg, range 51-77 kg) were offered Mepolizumab. Four had IgE-weight combinations above 
the manufacturer’s recommended treatment boundaries for Omalizumab (mean IgE level 1512 
IU/ml, range 1031-2229 IU/ml). Three had previously received Omalizumab: one failed to respond 
and two developed allergic reactions resulting in treatment discontinuation.  
 
Blood eosinophil count evaluated after 3 or 4 Mepolizumab doses and decreased in all patients (mean 
pre-treatment 0.8±0.64 x 109 cells/L to mean 0.1±0.06 x 109 cells/L at the 3rd or 4th Mepolizumab 
dose). FEV1 z-score improved in only 2/7 patients (29%) after 4 Mepolizumab doses (mean ∆FEV1 z-
score -0.2±0.68). ACT score improved in 5/7 (71%) after 4 Mepolizumab doses with a mean ∆ACT score 
of 3.0±4.55. PAQLQ scores were assessed after the initial 3 Mepolizumab doses and improved or 
remained static in 5/7 patients (71%), mean ∆PAQLQ score of 0.9±1.84. 
 
After 12 months of Mepolizumab, FEV1 z-score improved from baseline in 2/7 (29%) (mean ∆FEV1 z-
score -2.2±2.14). In 3/7 patients (43%), the FEV1 z-score deteriorated with a year of Mepolizumab 
treatment and remained static in 2/7 patients. ACT improved from baseline in only 3/7 patients (43%), 
with a mean ∆ACT score 1.7±7.25. Mean ∆FeNO after 4 Mepolizumab doses was -15±29 ppb and after 
12 doses was -37±126 ppb. No serious adverse effects reported. 
 
Episodes of asthma attacks in relation to treatment timelines for each patient are shown in figure 1. 
Mean number of asthma attacks requiring high dose oral steroids in the 12 months prior to 
Mepolizumab was 5.0±1.73. Four patients required hospitalisation for severe attacks during this 
time:2 admitted once, 1 admitted twice, 1 admitted three times. Prior to Mepolizumab treatment, 
mean number of hospitalisations for these patients was 1.8±0.96. During treatment, only 1 patient 
required 2 hospitalisations for asthma attacks after 1 and 11 Mepolizumab doses. There was 
reduced frequency of severe attacks requiring high dose oral steroids (mean 1.1±1.07 after 4 doses 
and mean 3.1±3.13 after 12 doses) with 1 patient (14%) having no severe attacks during 
Mepolizumab treatment. Although there was an overall improvement in the frequency of 
hospitalisations and severe attacks during Mepolizumab, 2 patients (patients 6 and 7) appear to be 
non-responders.  
 
DISCUSSION 
In these adolescents with eosinophilic asthma not eligible for Omalizumab or who had not benefited 
from it, Mepolizumab reduced asthma attacks in frequency or severity for the majority, similar to 
findings reported in adults and limited data available in adolescents [5,6,7]. We confirmed that while 
Mepolizumab reduced eosinophils to zero, those with a higher baseline eosinophil blood count did 
not respond better. There was less response of FeNO to Mepolizumab, consistent with findings by 
Halder et al [18] and Pavord et al [5], confirming a weak correlation between these markers and 
suggesting two different inflammatory pathways [19]. We found that Mepolizumab did not bring any 
consistent improvement in lung function, ACT or PAQLQ scores.  However, all patients subjectively 
reported positive feedback on their asthma control. Review at 4 and 12 months highlight that a 4-
month evaluation as is performed for Omalizumab, is not sufficient time to assess the effect of 
Mepolizumab on asthma attacks and we recommend a 12-month evaluation.  
 
Limitations 
This was a retrospective review of a small number of adolescents managed with Mepolizumab 
within clinical practice with no control group.  
 
CONCLUSION 
Mepolizumab 100mg given subcutaneously at monthly intervals was well tolerated in adolescents 
with severe eosinophilic asthma who were either ineligible for or who had failed on Omalizumab. 
Over a 12-month period of evaluation, it had a positive effect on reducing risk of asthma 
exacerbations. Further studies comparing the effectiveness of Omalizumab and Mepolizumab in 
children who are eligible for both will be required to determine who best to use these drugs in 
children with severe asthma. 
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Figure 1
Figure 1 legend
Illustration of asthma attacks over time. The blue part of each timeline represents 12 months pre-
Mepolizumab and yellow represents 12 months during Mepolizumab treatment (each subunit 
being 1 month), with the vertical black line highlighting commencement of Mepolizumab. Vertical 
green lines highlight when Mepolizumab was given. The red arrows represent hospitalisations for 
severe asthma attacks and the blues arrows represent patient reported asthma attacks requiring 
a course of oral steroids. 
